Metraipolis › archive › dc_7c2591a14901

Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection — Europe PMC PMID:41263140

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41263140
DOI
10.1002/jmv.70713
License (as archived)
solo-consultazione
Archived
2026-11-08T21:12:48.079Z
SHA-256 of the archived text
aeb68b8b43287833b295b803b66fdf1631e272ce343f880773e9a754b588895d
Stable URL of this page
https://metraipolis.com/documento/dc_7c2591a14901

How to cite

Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection — Europe PMC PMID:41263140 — Europe PMC (en), https://europepmc.org/article/MED/41263140 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7c2591a14901 (Metraipolis archive dc_7c2591a14901, sha256 aeb68b8b43287833b295b803b66fdf1631e272ce343f880773e9a754b588895d)
BibTeX
@misc{dc7c2591a14901,
  title = {Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection — Europe PMC PMID:41263140},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41263140},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7c2591a14901; sha256 aeb68b8b43287833b295b803b66fdf1631e272ce343f880773e9a754b588895d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41263140. Agents can read the archived copy with the MCP tool read_document.